Causes and Factors Associated with Early Failure in Hospitalized Patients with Community-Acquired Pneumonia

Archives of Internal Medicine

Volumn 164, Issue 5, 2004, Pages 502-508

  Rosón, Beatriz ^a   Carratalà, Jordi ^a   Fernández Sabé, Núria ^a   Tubau, Fe ^a   Manresa, Frederic ^a   Gudiol, Francesc ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; ETHAMBUTOL; GENTAMICIN; ISONIAZID; LEVOFLOXACIN; MACROLIDE; PIPERACILLIN; QUINOLONE DERIVATIVE; RIFAMPICIN; TAZOBACTAM; TOBRAMYCIN;

ADULT; AGED; AGING; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FEVER; GRAM NEGATIVE BACTERIUM; HOSPITALIZATION; HOST PATHOGEN INTERACTION; HUMAN; LEGIONELLA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NONHUMAN; PATIENT COMPLIANCE; PLEURA EMPYEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIODIAGNOSIS; RISK FACTOR; SEPSIS; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; EMPYEMA, PLEURAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE;

EID: 1542347642     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.5.502     Document Type: Article

References (30)

1. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med. 1995;333:1618-1624.
2. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis. 1989;11:586-599.
3. Mundy LM, Auwaerter PG, Oldach D, et al. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med. 1995;152:1309-1315.
4. Rosón B, Carratalà J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology, reasons for hospitalization, risk classes and outcomes of patients with community-acquired pneumonia hospitalized on the basis of conventional admission criteria. Clin Infect Dis. 2001;33:158-165.
5. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA. 1996;275:134-141.
6. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team Cohort Study. Arch Intern Med. 2002;162:1059-1064.
7. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-382.
8. The ATS Board of Directors. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418-1426.
9. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the Initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis. 2000;31:383-421.
10. British Thoracic Society Standards of Care Committee. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax. 2001;56 (suppl 4):IV1-IV64.
11. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279:1452-1457.
12. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Tenth Informational Supplement (Aerobic Dilution). Wayne, Pa: National Committee for Clinical Laboratory Standards; 2000. Document M100-S10 (M7).
13. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250.
14. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicroblal Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard Fifth Edition. Wayne, Pa: National Committee for Clinical Laboratory Standards; 2000. Document M7-A5; supplemental tables M100-S10.
15. Ortqvist A, Kalin M, Lejdeborn L, Lundberg B. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia. Chest. 1990;97:576-582.
16. Ewig S, Schlochtermeier M, Göke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest. 2002;121:1486-1492.
17. Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med. 2000;162:154-160.
18. File TM Jr. Optimal treatment strategies for community-acquired pneumonia: non-responders to conventional regimens. Chemotherapy. 2001;47(suppl 4):11-18.
19. Glynn P, Coakley R, Kilgallen I, Murphy N, O'Neill S. Circulating interleukin6 and interleukin 10 in community-acquired pneumonia. Thorax. 1999;54:51-55.
20. Kolling UK, Hansen F, Braun J, Rink L, Katus HA, Dalhoff K, Leucocyte response and anti-inflammatory cytokines in community-acquired pneumonia. Thorax. 2001;56:121-125.
21. Marik PE. The clinical features of severe community-acquired pneumonia presenting as septic shock: Norasept II Study Investigators. J Crit Care. 2000;15:85-90.
22. Musher DM, Alexandraki I, Graviss EA, et al. Bacteremic and nonbacteremic pneumococcal pneumonia: a prospective study. Medicine (Baltimore). 2000;79:210-221.
23. Tan MJ, Tan JS, Hamor RH, File TM Jr, Breiman RF. The radiologic manifestations of Legionnaire's disease: the Ohio Community-Based Pneumonia Incidence Study Group. Chest. 2000;117:398-403.
24. Heat CH, Grove DI, Looke DF. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis. 1996;15:286-290.
25. Mulazimoglu L, Yu VL. Can Legionnaires disease be diagnosed by clinical criteria? a critical review. Chest. 2001;120:1049-1053.
26. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: Incidence, risk, and prognosis. Arch Intern Med. 2002;162:1849-1858.
27. Rosón B, Carratalà J, Verdaguer R, et al. Prospective study on the usefulness of sputum gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis. 2000;31:869-874.
28. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azythromycin and clarithromycin. Clin Infect Dis. 2000;31:1008-1011.
29. Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:630-631.
30. Davidson R, Cavalcante R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:747-750.